

Jose-Antonio Perez-Simon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8912309/publications.pdf>

Version: 2024-02-01

59
papers

1,714
citations

304701

22
h-index

289230

40
g-index

63
all docs

63
docs citations

63
times ranked

2884
citing authors

#	ARTICLE	IF	CITATIONS
1	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , 2006, 107, 3575-3583.	1.4	188
2	Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. <i>Haematologica</i> , 2011, 96, 1072-1076.	3.5	155
3	Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2663.	4.1	118
4	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.	2.5	110
5	Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 102, 1108-1113.	1.4	100
6	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>British Journal of Haematology</i> , 2003, 121, 104-108.	2.5	90
7	Chronic Graft-Versus-Host Disease. <i>Drugs</i> , 2006, 66, 1041-1057.	10.9	71
8	Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes. <i>Blood</i> , 2019, 133, 224-236.	1.4	69
9	First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 4260-4273.	1.6	59
10	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020, 55, 641-648.	2.4	58
11	Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. <i>Haematologica</i> , 2009, 94, 975-983.	3.5	51
12	Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. <i>Leukemia</i> , 2021, 35, 201-214.	7.2	48
13	Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. <i>Blood Reviews</i> , 2021, 48, 100792.	5.7	48
14	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1050-1058.	2.4	42
15	Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 80-86.	0.4	40
16	Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 5673-5681.	7.0	39
17	Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 151-158.	1.7	38
18	Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. <i>British Journal of Haematology</i> , 2013, 162, 474-482.	2.5	36

#	ARTICLE	IF	CITATIONS
19	Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 236-244.	0.4	31
20	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.	2.0	29
21	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.	3.5	27
22	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021, 100, 1181-1194.	1.8	27
23	Cholinergic signals preserve haematopoietic stem cell quiescence during regenerative haematopoiesis. <i>Nature Communications</i> , 2022, 13, 543.	12.8	25
24	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 1187-1195.	3.5	15
25	The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. <i>Haematologica</i> , 2012, 97, 1329-1337.	3.5	15
26	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10.	0.8	15
27	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	3.5	15
28	<i>ASXL1</i> mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. <i>Cancer Medicine</i> , 2020, 9, 3637-3646.	2.8	14
29	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2042-2047.	2.0	13
30	Noninvasive prenatal diagnosis by cell-free DNA screening for fetomaternal HPA class I a platelet incompatibility. <i>Transfusion</i> , 2018, 58, 2272-2279.	1.6	13
31	Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. <i>Clinical Cancer Research</i> , 2019, 25, 4616-4623.	7.0	13
32	Evolving treatment patterns and outcomes in older patients (>60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	7.2	12
33	Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology". <i>Frontiers in Immunology</i> , 2018, 9, 1971.	4.8	11
34	Intermediate doses of cytarabine plus granulocyte colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure. <i>Transfusion</i> , 2015, 55, 875-879.	1.6	9
35	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome*. <i>Leukemia and Lymphoma</i> , 2017, 58, 1893-1902.	1.3	9
36	PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 2217-2224.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells. <i>Cell Death and Differentiation</i> , 2018, 25, 1967-1979.	11.2	7
38	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1001-1014.	4.2	7
39	<i>ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells</i>. <i>Blood</i> , 2020, 136, 13-14.	1.4	7
40	Evaluation of a method for murine monocyte isolation by bone marrow depletion. <i>Analytical Biochemistry</i> , 2015, 480, 42-48.	2.4	5
41	Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 258.e1-258.e8.	1.2	4
42	Effect of Vitamin D on Graft-versus-Host Disease. <i>Biomedicines</i> , 2022, 10, 987.	3.2	4
43	An Active Isodicentric X Chromosome in a Case of Refractory Anaemia with Ring Sideroblasts Associated with Marked Thrombocytosis. <i>Case Reports in Genetics</i> , 2014, 2014, 1-3.	0.2	3
44	Intravascular lymphoma: look through the small vessels. <i>Annals of Hematology</i> , 2017, 96, 517-519.	1.8	3
45	Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 3049-3058.	2.4	3
46	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.8	3
47	Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases. <i>Antibiotics</i> , 2021, 10, 136.	3.7	2
48	Pre-Clinical Trial to Evaluate the Efficacy of Delayed Administration of Ixazomib in the Prophylaxis of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 4521-4521.	1.4	2
49	<i>Candida parapsilosis</i> misleading the automated absolute and differential white blood cell count. <i>Annals of Hematology</i> , 2017, 96, 169-170.	1.8	1
50	MUFAs in High-Fat Diets Protect against Obesity-Induced Bias of Hematopoietic Cell Lineages. <i>Molecular Nutrition and Food Research</i> , 2021, 65, 2001203.	3.3	1
51	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
52	Effect of Mesenchymal Stem Cells on the Viability, Proliferation and Differentiation of B Lymphocytes.. <i>Blood</i> , 2007, 110, 3880-3880.	1.4	0
53	Prognostic Impact of Adverse Karyotype and Treatment in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 5241-5241.	1.4	0
54	Pronostic Value of Pretransplant Echocardiography in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 4363-4363.	1.4	0

#	ARTICLE	IF	CITATIONS
55	An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3142-3142.	1.4	0
56	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 2955-2955.	1.4	0
57	The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma. <i>Blood</i> , 2015, 126, 2007-2007.	1.4	0
58	Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen. <i>Blood</i> , 2015, 126, 4373-4373.	1.4	0
59	Clinical Outcome, Molecular and Gene Expression Analysis of 20 MLL-Rearranged AML from a Single Institution. <i>Blood</i> , 2015, 126, 4943-4943.	1.4	0